JPH05331064A - Anti-inflammatory analgesic plaster - Google Patents

Abstract

PURPOSE:To provide an anti-inflammatory analgesic plaster free from skin stimulation and containing indomethacin in a state having improved solubility in the base agent and, accordingly, improved permeability to skin. CONSTITUTION:The plaster is produced by applying a plaster layer composed of a rubber-based tacky adhesive base containing a pharmaceutical agent and a dissolution assistant to a surface of a substrate. The rubber-based tacky adhesive base contains (A) 70-95wt.% of a 10-30C paraffinic hydrocarbon and/or naphthenic hydrocarbon and a tackifier resin and (B) 5-30wt.% of a styrene- based thermoplastic elastomer. The ratio of the hydrocarbon to the tackifier resin is 2:3 to 3:2. The pharmaceutical agent is indomethacin and the dissolution assistant is one or more substances selected from benzyl alcohol, crotamiton, glycol salicylate, urea and polyvinylpyrrolidone.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an anti-inflammatory and analgesic patch containing indomethacin and having a low irritation and a high release.

[0002]

BACKGROUND OF THE INVENTION Indomethacin is 1- (p-chlorobenzoyl) -5-methoxy-2-methylidol-3-acetic acid (molecular formula C ₁₉ C ₁₆ ClNO ₄ , molecular weight 357.79).
It is an excellent non-steroidal anti-inflammatory and analgesic drug having the chemical name of, and is widely applied to the treatment of various anti-inflammatory patients such as rheumatoid arthritis and osteoarthritis, and post-operative inflammation. Dosage forms of indomethacin generally include oral agents, suppositories, ointments, etc., in order to eliminate the side effects of concern with oral administration and suppository administration, and further to improve the feeling of discomfort seen in ointments, A patch for directly administering this locally has been proposed.

Conventionally, as a patch containing indomethacin as an active ingredient, one in which indomethacin is dissolved or dispersed in a specific acrylic polymer, or a patch (JP-A-61-277)
No. 615), and a mixture of them with an absorption aid (see Japanese Patent Publication No. 60-19890).

[0004]

However, these patches are not always satisfactory in the diffusion mobility of indomethacin in the acrylic polymer and the release of indomethacin from the polymer into the skin. There wasn't.

A patch using a rubber-based pressure-sensitive adhesive prepared by compounding a rubber elastic body such as natural rubber or polyisoprene rubber, a tackifying resin and a softening agent as the pressure-sensitive adhesive generally has a low adhesiveness at the time of application. On the other hand, on the other hand, when peeled off, the stratum corneum of the skin was peeled off due to its strong adhesive force, causing a rash on the skin and causing undesired phenomena such as bruising of body hair.

Further, of the bases that can generally be used as external preparations, very few indomethacin exhibit high solubility, and especially indomethacin has a low solubility in rubber-based adhesive bases. There was a risk that crystals of indomethacin would precipitate and the amount of drug permeating through the skin would decrease.

The present invention has been made in view of the above-mentioned circumstances, and its object is to cause no irritation to the skin and good solubility of indomethacin in a base material, thus improving the skin permeation amount of indomethacin. It is to provide an anti-inflammatory analgesic patch.

[0008]

The anti-inflammatory and analgesic patch according to the present invention has been devised in order to achieve the above-mentioned object, in which a styrene thermoplastic elastomer is used as a rubber elastic body and a rubber-based adhesive group is used. It has been completed based on the finding that the desired anti-inflammatory and analgesic patch as described above can be obtained by including a specific content in the agent.

That is, the anti-inflammatory and analgesic patch according to the present invention is a patch in which a plaster layer made of a rubber-based adhesive base containing a drug and a dissolution aid is provided on one side of a support.
The rubber-based pressure-sensitive adhesive base contains 70 to 95% by weight of a paraffinic hydrocarbon having 10 to 30 carbon atoms and / or naphthenic carbon-hydrogen and a tackifying resin, and 5 to 30% by weight of a styrene-based thermoplastic elastomer. And the content ratio of the hydrocarbon to the tackifying resin is 2: 3 to 3: 2, the drug is indomethacin, and the dissolution aid is benzyl alcohol, crotamiton, glycol salicylate, urea and polyvinyl. It is at least one selected from the group consisting of pyrrolidone.

Hereinafter, each component of the anti-inflammatory and analgesic patch according to the present invention, manufacturing method, etc. will be described in detail.

A) A styrene-based thermoplastic elastomer which is a constituent of a rubber-based adhesive base is styrene.
Isoprene block copolymer, styrene / isoprene /
Examples thereof include synthetic rubbers such as styrene block copolymers, styrene / butadiene block copolymers, styrene / butadiene / styrene block copolymers, styrene / ethylene / butadiene / styrene block copolymers. The copolymer is obtained by dissolving styrene in cyclohexane or the like and polymerizing it in the presence of a catalyst to form a thermoplastic block (polystyrene), which is then polymerized with a rubber block to obtain an intermediate block copolymer, to which a coupling agent is added. Is added, and the intermediate block copolymers are coupled to each other to obtain the compound. The solution viscosity of the copolymer is 2
A styrene / rubber ratio of 10/90 to 50 at about 100 to 50,000 centipoise (cP) in a 5% toluene solution.
Those having a weight ratio of / 50% by weight are preferably used.

Further, as the liquid polymer component, polyisobutylene and polybutene (average molecular weight of 500 to 5,50) are used.
0), liquid polyisoprene, and the like, which are compatible with the styrene-based thermoplastic elastomer, may be appropriately mixed with the elastomer. Of these, polybutene is the most suitable. The liquid polymer component is generally used in the rubber-based adhesive base in an amount of about 10% by weight or less.

The proportion of the styrene thermoplastic elastomer in the rubber adhesive base is 5 to 30% by weight. When this ratio is less than 5% by weight, the adhesive force of the rubber-based adhesive base is low, and thus adhesive residue or the like occurs during peeling. Further, if the ratio of the styrene-based thermoplastic elastomer in the rubber-based adhesive base is more than 30% by weight, the adhesive strength of the rubber-based adhesive base becomes too strong, and repeated application cannot be performed, resulting in keratin peeling or hair peeling. Peeling occurs and irritation increases.

B) 10 to 3 carbon atoms used in the present invention
Examples of the paraffinic hydrocarbon and / or naphtheneic hydrocarbon of 0 include light liquid paraffin, heavy liquid paraffin, hexamethyltetracosane, hexamethyltetracosahexane, α-olefin oligomer, etc. Alternatively, they are used in combination of two or more.

Paraffin hydrocarbons and / or naphthene hydrocarbons having 31 or more carbon atoms are solid at room temperature and do not have sufficient softening properties when compounded with a tackifying resin or a styrene thermoplastic elastomer. A patch having good adhesive strength cannot be obtained. Those having 9 or less carbon atoms are not preferable because the softening property becomes high and the plaster layer becomes too soft.

Examples of the tackifying resin used in the present invention include rosin resins (rosin, hydrogenated rosin, esters thereof, etc.), polyterpene resins, coumarone-isoden resins, petroleum resins (aliphatic and alicyclic resins). Etc.), terpene-
Softening point 50 to 12 selected from the group of phenolic resins
The thing of 0 degreeC is illustrated, and these are used individually or in combination of 2 or more. The blending ratio of the tackifying resin is appropriately determined so that the tackiness at the time of sticking and the hair peeling at the time of peeling do not occur. The petroleum-based resin is prepared by cationically polymerizing diolefins and monoolefins contained in the C ₅ fraction and the C ₉ fraction obtained during naphtha decomposition in the presence of a Friedel-Craft catalyst. Those produced and having a molecular weight of 500 to 2,000 are preferably used.

The total amount of the paraffinic hydrocarbon having 10 to 30 carbon atoms and / or naphthenic carbon hydrogen and the tackifying resin is 70 to 95% by weight in the rubber adhesive base. If this ratio is more than 95% by weight, the adhesive strength of the adhesive is low, and adhesive residue or the like occurs during peeling. In addition, this ratio is 7
If it is less than 0% by weight, the adhesive strength will be too strong.
It cannot be applied repeatedly, resulting in exfoliation and exfoliation of the keratin, resulting in increased irritation.

If the content ratio of the paraffinic hydrocarbon and / or naphtheneic hydrocarbon to the tackifying resin is larger than 3: 2, the sticking property may be poor and the adhesive residue may be left after peeling. .. On the other hand, if this ratio is less than 2: 3, exfoliation of the keratin and peeling of the hair occur during exfoliation, and repeated application is not possible. Therefore, it can be repeatedly applied without impairing the adhesiveness when applied, and
In order to provide a hypoallergenic patch that relieves hair grimacing during peeling and physical irritation to the skin, the content ratio of the paraffin hydrocarbon and / or naphthene hydrocarbon and the tackifying resin is: 2: 3 to 3: 2.

C) Indomethacin has a medicinal effect as described above. The content of indomethacin is not particularly limited as long as it has a therapeutic effect,
Generally, it is in the range of 0.05 to 5% by weight in the plaster. If the content of indomethacin is too low, the anti-inflammatory and analgesic effect is low, and if it is too high, irritation is expressed or it is difficult to dissolve it uniformly in the plaster, so the preferred range is 0.1-2.
% By weight.

D) As the solubilizing agent used in the present invention, at least one selected from the group consisting of benzyl alcohol, crotamiton, glycol salicylate, urea and polyvinylpyrrolidone is blended. The dissolution aid is
It is added in consideration of the solubility of indomethacin, the feeling of use and skin irritation of the patch of the present invention, and the content thereof is not particularly limited, but it is generally 0 in the plaster layer. It is in the range of 0.5 to 20% by weight.

Further, if necessary, an antiaging agent, an antioxidant, a filler, a pH adjusting agent and the like may be added to the plaster layer as appropriate.

E) Materials for the support used in the present invention include non-woven fabric, woven fabric, polyester, polyethylene,
Examples thereof include polyvinyl chloride, polyvinylidene chloride, ethylene-vinyl acetate copolymer, polyurethane and laminated films thereof. Among these, the material having low moisture permeability is preferably subjected to physicochemical processing to impart moisture permeability. This treatment is to prevent skin irritation due to excessive stuffiness. Further, it is desirable that the support has a function of expanding and contracting in at least one direction, and a material having no such function is preferably subjected to appropriate expansion and contraction processing. This is because if the support has a stretching function, it can follow the stretching of the skin surface when the patch is attached to the body. The thickness of the support is preferably 5 to 2,000 μm.

F) Examples of the release paper used in the present invention include polyester, polypropylene, polyethylene-coated high-quality paper, polyethylene-coated glassine paper, and the like whose upper surface is treated with silicon. The thickness of the release paper is preferably 20 to 200 μm.

G) The patch according to the present invention comprises a mixture of a paraffinic hydrocarbon and / or a naphthene hydrocarbon, a tackifying resin and a rubber-based adhesive base component composed of a styrene thermoplastic elastomer, indomethacin and a dissolution aid. To obtain a plaster, which is spread on a release paper (or a support) and dried by a solvent method described below to remove the solvent, and the resulting paste (or a support) on the plaster layer. It is manufactured by laminating release paper).

Typical examples of the method for obtaining the plaster of this patch include solvent method and hot melt method. When the solvent method is applied, a solvent is added to the mixture of the rubber-based pressure-sensitive adhesive base component, indomethacin and the dissolution aid, and this is uniformly dissolved to obtain a plaster. Examples of the solvent used include those compatible with the rubber-based adhesive base, indomethacin and the dissolution aid, for example, tetrahydrofuran, chloroform and methylene chloride. However, among the dissolution aids, polyvinylpyrrolidone is difficult to dissolve unless it is an alcohol solvent, so it is advisable to first dissolve it in methanol or the like and then mix it with other components.

When the hot melt method is applied,
A predetermined amount of each component of the rubber-based adhesive base is blended,
Under nitrogen substitution, the mixture is heated and mixed at a temperature of 90 to 180 ° C. to melt. After melting, the temperature of the adhesive base is lowered to 60 to 150 °, indomethacin and a dissolution aid are added, and the mixture is uniformly mixed to obtain a plaster.

In producing the plaster, whether by the solvent method or the hot melt method, the order of addition of the base and the medicinal components is appropriately set in consideration of the characteristics of the obtained plaster and the ease of operation. Alternatively, heating or ultrasonic treatment may be performed in order to accelerate dissolution or melting.

G) The area of the adhesive patch of the present invention is preferably about 35 to about 140 cm ^{2 in} consideration of the application site and usability. Further, the plaster thickness of the patch is preferably 50 to 1, in consideration of the concentration of indomethacin, coatability and the like.
The thickness is 000 μm, more preferably 50 to 300 μm.

[0029]

EFFECTS OF THE INVENTION Since the present invention is constituted as described above, it provides an anti-inflammatory analgesic patch which has no irritation to the skin and good solubility of indomethacin in the base, and thus has improved skin permeation amount of indomethacin. be able to.

[0030]

EXAMPLES Examples of the present invention will be described below. In the following, parts and% mean parts by weight and% by weight, respectively.

Example 1 SIS 15 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 42.5 parts Liquid paraffin 37.5 parts Indomethacin 0.5% Crotamiton 2% SIS (styrene-isoprene-styrene block copolymer) , Styrene-rubber ratio (wt%): 14/8
Solution viscosity in 6,25 wt% toluene solution: 1,60
0cP, "Califlex TR1107" manufactured by Shell Chemical Co., Ltd., polybutene (average molecular weight about 1350, "Nisseki Polybutene" manufactured by Nippon Petrochemical Co., Ltd.), alicyclic saturated hydrocarbon resin (softening point 90 ° C, molecular weight 630, "Arcon" P90 "Arakawa Chemical Industry Co., Ltd."), liquid paraffin (heavy liquid paraffin, Nikko Pharmaceutical Co., Ltd.) rubber-based adhesive base components are blended in the above proportions, and heat-mixed at a temperature of 120 to 150 ° under nitrogen substitution. And melted. After melting, the temperature of the adhesive base is 100-
After dropping to 120 °, indomethacin and crotamiton were added and mixed uniformly to obtain a plaster.

Next, the molten paste was spread on a release paper (polyethylene-coated high-quality paper, thickness: about 140 μm) with a hot melt coater to obtain a paste layer having a thickness of about 150 μm. Finally, on this plaster layer, a styrene-butadiene / polypropylene film with a thickness of approximately 240 μm and a basis weight of 70 g
/ M ² of nonwoven fabric was laminated as a support. Thus, an anti-inflammatory analgesic patch containing indomethacin was obtained.

Example 2 SIS 15 parts Alicyclic saturated hydrocarbon resin 45.5 parts Liquid paraffin 39.5 parts Indomethacin 0.5% Benzyl alcohol 2% Polybutene was removed from the formulation of Example 1 instead of crotamiton, benzyl. An indomethacin-containing anti-inflammatory analgesic patch was obtained in the same manner as in Example 1 except that alcohol was used.

Example 3 SIS 15 parts polybutene 5 parts alicyclic saturated hydrocarbon resin 42.5 parts liquid paraffin 37.5 parts indomethacin 0.4% glycol salicylate 2% In the formulation of Example 1 glycol salicylate instead of crotamiton. An indomethacin-containing anti-inflammatory analgesic patch was obtained in the same manner as in Example 1 except that was used.

Example 4 SIS 15 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 42.5 parts Liquid paraffin 37.5 parts Indomethacin 0.5% Urea 2% Urea is used in place of crotamiton in the formulation of Example 1. Indomethacin-containing anti-inflammatory analgesic patch was obtained in the same manner as in Example 1 except that

Example 5 SIS 15 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 42.5 parts Liquid paraffin 37.5 parts Indomethacin 0.5% Polyvinylpyrrolidone 0.7% Instead of crotamiton in the formulation of Example 1. An indomethacin-containing anti-inflammatory analgesic patch was obtained in the same manner as in Example 1 except that polyvinylpyrrolidone (kollidon 90F, manufactured by BASF) was used.

Example 6 SIS 25 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 34 parts Liquid paraffin 36 parts Indomethacin 0.5% Crotamiton 2% In the composition of Example 1, the mixing ratio of each component was as described above. An indomethacin-containing anti-inflammatory analgesic patch was obtained in the same manner as in Example 1 except that it was changed.

Comparative Example 1 SIS 4 parts Alicyclic saturated hydrocarbon resin 43 parts Liquid paraffin 53 parts Indomethacin 0.5% Crotamiton 2% Using the above formulation, indomethacin-containing anti-inflammatory analgesic was obtained in the same manner as in Example 1. It was

Comparative Example 2 SIS 32 parts Alicyclic saturated hydrocarbon resin 35 parts Liquid paraffin 33 parts Indomethacin 0.5% Crotamiton 2% Using the above formulation, indomethacin-containing anti-inflammatory analgesic was obtained in the same manner as in Example 1. It was

Comparative Example 3 SIS 28 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 47 parts Liquid paraffin 20 parts Indomethacin 0.5% Crotamiton 2% Indomethacin-containing anti-inflammatory analgesic was prepared in the same manner as in Example 1 using the above formulation. I got an agent.

Comparative Example 4 SIS 15 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 25 parts Liquid paraffin 55 parts Indomethacin 0.5% Crotamiton 2% Indomethacin-containing anti-inflammatory analgesia was prepared in the same manner as in Example 1 using the above formulation. I got an agent.

Comparative Example 5 SIS 15 parts Polybutene 5 parts Alicyclic saturated hydrocarbon resin 42.5 parts Liquid paraffin 37.5 parts Indomethacin 0.5% Except that crotamiton was omitted from the formulation of Example 1, Similarly, an indomethacin-containing anti-inflammatory analgesic patch was obtained.

Comparative Example 6 Acrylic adhesive (solid content) 78.5% Indomethacin 10% Isopropyl myristate 10% Coconut oil fatty acid monoethanolamide 1.5% 2-Ethylhexyl acrylate 65 mol% (302.
0 g), N-vinyl-2-pyrrolidone 35 mol% (9
8.0 g) and hexamethylene glycol dimethacrylate 0.01 wt% (40.0 mg) were charged in a separable flask, and the monomer concentration at the initial stage of polymerization was 85 wt%.
Then, 70.6 g of ethyl acetate was added thereto. This solution was heated to 60 ° C. under a nitrogen atmosphere, a polymerization initiator solution prepared by dissolving lauroyl peroxide in ethyl acetate was added little by little, and a polymerization reaction was carried out for 32 hours. The total amounts of lauroyl peroxide and ethyl acetate added during this polymerization were 4 g and 535 g, respectively. Thus, an acrylic adhesive having a molecular weight of about 700,000 was obtained.

To this acrylic adhesive (solid content conversion),
Indomethacin, isopropyl myristate (absorption aid) and coconut oil fatty acid monoethanolamide (absorption aid) were added in the above proportions, and ethyl acetate was used as a solvent so that the total solid content of the coating solution was about 34% by weight. In addition to the above, the above composition was uniformly dissolved in a solvent to obtain a coating liquid.

The obtained coating solution was applied on a release paper made of a polyethylene-treated polyethylene terephthalate film so that the thickness of the dried paste layer was 75 μm, and the applied layer was placed in an oven at 60 ° C. for 30 minutes. It was dried to form a plaster layer. A pair of release paper / paste layer composites thus obtained is prepared, and each plaster layer is overlaid to have a thickness of 1
A 50 μm plaster layer was prepared. Next, after peeling off one of the release papers, a nonwoven fabric similar to the nonwoven fabric of Example 1 was laminated on the surface as a support.

Performance Test A performance test was conducted on the patches obtained in Examples and Comparative Examples by the following method.

<Paste Test> Examples 1, 2, 6 and Comparative Example 1
With respect to each patch (3 × 4 cm) of ~ 6, a patch test on human skin was conducted as follows. That is, the patch was attached to the upper arms of 10 (normal and male) subjects,
After 6 hours, adhesiveness, adhesive residue, peeling when peeling,
Each patch was evaluated for the five items of pain during exfoliation and exfoliation of the keratin. The number of repetitions was 2 times. The results of this sticking test are shown in Table 1.

<Permeability Test> Example 1, Comparative Examples 3 and 5,
For each patch of No. 6, a permeation test was carried out using the hairless mouse excised skin by the following method, and after 24 hours, the cumulative permeation amount of indomethacin was determined. The results of the permeability test are shown in Table 2 and the graph of FIG.

First, a Franz type diffusion cell (1) shown in the attached FIG. 2 was prepared. The diffusion cell (1) comprises a bottomed cylindrical receptor tank (2) and a bottomed cylindrical donor tank (3) arranged thereon. An opening (4) is provided in the center of the bottom wall of the donor tank (3), and an upper flange (5) and a lower flange (6) are provided at the lower end of the donor tank (3) and the upper end of the receptor tank (2), respectively. ) Is provided. Then, by overlapping the upper flange (5) and the lower flange (6) so as to face each other, the donor tank (3) and the receptor tank (3) are
(2) are stacked airtightly and concentrically. A laterally projecting sampling port (7) is attached to the side of the receptor tank (2), and a magnetic stirrer (9) is placed inside the receptor tank (2).

After hairless mice (6 weeks old, male) were sacrificed by cervical dislocation, the back skin was immediately peeled off to remove the subcutaneous fat and muscle layer to obtain a skin piece of about 4 cm × 4 cm.
This piece of skin (8) was clamped between the upper flange (5) and the lower flange (6) of the diffusion cell (1) to open the opening of the donor tank (3).
(4) was made to completely close with the skin piece (8).

A test piece punched out in an area of 3.14 cm ² was attached to the upper surface of the skin piece (8).

The receptor tank (2) was filled with a receptor liquid having the composition shown in Table 4.

Next, the diffusion cell (1) was placed in a constant temperature bath kept at a temperature of 37 ° C., and the receptor liquid was stirred by a magnetic stirring device. For 24 hours after the start of the test, 1 ml of the receptor solution was sampled from the sampling port (7) at every required time, and immediately after that, the receptor solution was replenished, and the permeation amount of the drug into the sampled receptor solution was measured by high performance liquid chromatography. It was measured. The number of test pieces was three for each formulation.

<Drug Compatibility Test> With respect to each patch of Examples 1 to 6 and Comparative Example 5, after production, 2 at room temperature and 60 ° C.
The presence or absence of crystal precipitation of indomethacin under each storage condition for a week was observed. The results are shown in Table 3.

[0055]

[Table 1] 1) Adhesiveness: Evaluation of adhesiveness after applying 3 × 4 cm tape to the upper arm for 6 hours Good: Residual adhesive area of the tape was 95% or more Poor: Residual adhesive area of the tape was 75% or less 2) Adhesive residue: Evaluation of whether or not the adhesive remains on the skin after peeling. +: The adhesive remains on the skin after peeling.

-: No adhesive remained on the skin after peeling.

3) Peeling at the time of peeling: Evaluation of whether hair bristles of the body hair are generated at the time of peeling Yes: There was hair plucking None: There was no hair plucking 4) Pain at the time of peeling: About pain at the time of peeling Evaluation by a sensory test None: No pain was felt Pain: Pain was felt during peeling 5) Exfoliation of the keratin: Evaluation of whether or not exfoliation of the stratum corneum of the skin occurs during exfoliation ++: Overall exfoliation at the application site Layer peeled +: Some keratinous peeling was observed at the applied site-: No keratinous peeling was observed As is clear from Table 1, the patch of the example is excellent in all test items. Is recognized.

[0058]

[Table 2] As is clear from Table 2 and the graph of FIG. 1, it is recognized that the patches of the examples show excellent permeability as compared with those of the comparative examples.

[0059]

[Table 3] +: Crystallization of indomethacin was observed after 2 weeks under each temperature condition.

-: No crystal precipitation of indomethacin was observed after 2 weeks under each temperature condition.

Since the patch of the example contained a dissolution aid, no indomethacin was deposited, but the patch of the comparative example containing no dissolution aid deposited indomethacin.

[0062]

[Table 4]

[Brief description of drawings]

FIG. 1 is a graph showing the results of a permeability test.

FIG. 2 is a perspective view showing a Franz type diffusion cell.

Claims (1)

[Claims] 1. A patch having a plaster layer comprising a rubber-based pressure-sensitive adhesive base containing a drug and a dissolution aid on one surface of a support, wherein the rubber-based pressure-sensitive adhesive base has 10 to 30 carbon atoms. Paraffinic hydrocarbon and / or naphthenic carbon hydrogen and 70% to 95% by weight of tackifying resin, 5% to 30% by weight of styrene thermoplastic elastomer, and the content ratio of the hydrocarbon and tackifying resin. Is 2: 3 to 3: 2, the drug is indomethacin, and the solubilizing agent is at least one selected from the group consisting of benzyl alcohol, crotamiton, glycol salicylate, urea, and polyvinylpyrrolidone. An anti-inflammatory analgesic patch characterized by the following: